📣 We’re proud to announce the release of our 2023 ESG report. This report highlights our ongoing commitment and underscores our efforts to foster growth and responsible investment. ☑ Our portfolio companies are delivering significant benefits to clients and employees by creating innovative solutions and fostering better work environments. By leveraging advanced technologies, they are actively working to find solutions for the transition to a more sustainable world. ☑ Through our financing, these companies can expand their impact and deliver positive outcomes for all stakeholders. For deeper insights and a comprehensive overview of our journey towards responsible investing, we invite you to download the full report here 👉 https://lnkd.in/eZgNDWQh #Investment #ESG #Impact #VentureCapital Isabelle de Cremoux
Seventure Partners
Activités de placement pour compte propre
We actively fund innovative companies within the two evolving fields of Digital technologies and Life sciences.
À propos
Seventure Partners est un investisseur de long terme qui accompagne activement en capital les entreprises innovantes visant un impact positif sur l’Homme, la Société et la Planète. Avec 950 M€ sous gestion* à fin 2022, Seventure est un leader Européen du capital innovation et investit depuis 1997 dans des sociétés à fort potentiel de croissance évoluant dans deux principaux domaines d’activité : les Sciences de la vie (Biotechnologies, Santé & santé digitale, Nutrition, Alimentation, Nutrition, Blue Economy, Aquaculture, Animal & Agriculture, Sport & Bien-être …) avec un intérêt particulier pour les entreprises du microbiome, dans toute l’Europe ainsi qu’en Israël, Asie et Amérique du Nord, et les Technologies digitales (FinTech, RetailTech etc…) principalement en France et en Allemagne. Seventure accompagne le développement de sociétés depuis la création de l’entreprise (amorçage et premier tour), jusqu’à des tours de financement de capital développement (venture, growth, pre-IPO et IPO), avec des montants investis entre 500 K€ et 10 M€ par tour de financement, et jusqu’à 20 M€ par société.
- Site web
-
http://www.seventure.fr
Lien externe pour Seventure Partners
- Secteur
- Activités de placement pour compte propre
- Taille de l’entreprise
- 11-50 employés
- Siège social
- Paris
- Type
- Partenariat
- Fondée en
- 1997
- Domaines
- Venture Capital, Life sciences, Information and Communication Technology, Financement de l'innovation, Technologies digitales, Fintech, Microbiome, Dispositifs médicaux, Médicaments, Logiciels, Services innovants, Fonds de capital investissement, Sportech, Blue Economy, Healthtech et Agritech
Lieux
-
Principal
5-7 rue de Monttessuy
75007 Paris, FR
Employés chez Seventure Partners
-
Isabelle de Cremoux
CEO de Seventure Partners
-
Damien Dupouy
Entrepreneur - Building new ventures - Founder at Anytime (Sold to Orange in 2021)
-
Ludovic Denis
Venture Partner at Seventure
-
Leonor Lopes Gil
Membre du Comité de Direction Générale en charge Pôle Développement commercial et Secrétariat Général chez Banque Populaire Méditerranée (BPMED)
Nouvelles
-
🙌 Today, Thursday 27 June, is the International Microbiome Day! An opportunity to highlight the particularly intense development of research into the human #microbiome in 2023, and the major milestones that have been reached in terms of #therapeutic targeting. To find out more about current developments, download our report: 👉 ow.ly/5tMq50Ryf4M Isabelle de Cremoux #Microbiome #HealthforLifeCapital #Biotech #Research
-
-
Thank you to #InVivo (Norstella) for printing the article of Isabelle de Cremoux, our CEO, on the state of the #Biopharma market – not just from the POV of the companies, but also from the VCs that invest in them. In summary, Biopharma markets may follow the downward trajectory of tech during tough times, but they also chase it back up the value curve. Recovery is just a matter of time, however, in those tough times, that’s when innovation and resourcefulness can deliver valuable long-term benefits. #Microbiome #HealthforLifeCapital #Biotech #Pharma #PrivateEquity #Investment To read the full article, follow the link https://lnkd.in/eiBX75n3
-
🚀 Exciting News! We’re delighted to be part of Tubulis GmbH €128 Million Series B2 Funding Round which Seventure’s funds are supporting since 2020 🚀 Isabelle de Cremoux
Today marks a pivotal moment in the evolution of Tubulis. We have successfully closed an upsized and oversubscribed €128 million Series B2 #financing co-led by EQT Life Sciences and Nextech Invest, with participation from new US-based funds, Frazier Life Sciences and Deep Track Capital, as well as all of our existing investors. The support of this syndicate of leading global biotech investors underscores the potential of our unique approach to pioneering the next wave of truly differentiated, disease-specific #ADC therapeutics. With this funding, we are well-positioned to advance our next-generation ADCs into clinical evaluation and achieve clinical proof-of-concept for our lead #SolidTumor candidates, TUB-040 and TUB-030. The proceeds will also support the further development of our technology platforms to unlock novel payloads and the establishment of a US subsidiary to expand our corporate footprint. We look forward to working with Christoph Broja and Kanishka Pothula as new members of our Supervisory Board to realize our vision of providing new, high-quality treatment options for many hard-to-treat #cancers. Read the full PR here: https://bit.ly/3IxICOZ
-
Seventure Partners a republié ceci
"Microbiome Progress: A look at 2023" – our new report unveiled. 🙌 We are excited to announce publication of our new comprehensive report describing research advances in the human #microbiome in 2023. The author of the report, Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, assesses recent discoveries and developments and delves into the pivotal implications of these on health, clinical study progress, therapeutic, diagnostic, and nutritional products, and the food of tomorrow. To obtain a free copy of the report, please send your request throught this link 👉 https://lnkd.in/eTmGm4JS The report covers key themes: ✅ Understanding the Gut Microbiome: Exploring its composition and intricate link to human health. ✅ Therapeutic Breakthroughs: Targeting the microbiome to treat autoimmune, inflammatory, metabolic, and neurological disorders, with promising results already in cancer, autism, Parkinson's, and obesity. ✅ Tech-Driven Developments: Embracing data standardization and leveraging machine learning and AI to expedite data processing and research. ✅ Microbiome Products: State of play of first- and next-generation microbiome products, including fecal microbiome transplantation, Live Biotherapeutics, and more traditional drugs. ✅ Expanding Horizons: Venturing beyond the gut microbiome to target other human microbiomes, such as the oral cavity, skin, vagina, and lungs. *Beyond Medicine: Exploration of non-medicinal products – #prebiotics, #probiotics, #postbiotics, and #symbiotics. #BIOTECH #NUTRITION #DEEPTECH #FOODTECH #HEALTHFORLIFECAPITAL
-
-
"Microbiome Progress: A look at 2023" – our new report unveiled. 🙌 We are excited to announce publication of our new comprehensive report describing research advances in the human #microbiome in 2023. The author of the report, Isabelle de Cremoux, CEO and Managing Partner of Seventure Partners, assesses recent discoveries and developments and delves into the pivotal implications of these on health, clinical study progress, therapeutic, diagnostic, and nutritional products, and the food of tomorrow. To obtain a free copy of the report, please send your request throught this link 👉 https://lnkd.in/eTmGm4JS The report covers key themes: ✅ Understanding the Gut Microbiome: Exploring its composition and intricate link to human health. ✅ Therapeutic Breakthroughs: Targeting the microbiome to treat autoimmune, inflammatory, metabolic, and neurological disorders, with promising results already in cancer, autism, Parkinson's, and obesity. ✅ Tech-Driven Developments: Embracing data standardization and leveraging machine learning and AI to expedite data processing and research. ✅ Microbiome Products: State of play of first- and next-generation microbiome products, including fecal microbiome transplantation, Live Biotherapeutics, and more traditional drugs. ✅ Expanding Horizons: Venturing beyond the gut microbiome to target other human microbiomes, such as the oral cavity, skin, vagina, and lungs. *Beyond Medicine: Exploration of non-medicinal products – #prebiotics, #probiotics, #postbiotics, and #symbiotics. #BIOTECH #NUTRITION #DEEPTECH #FOODTECH #HEALTHFORLIFECAPITAL
-
-
Soil Microbotia: 👏 to Starfish bioscience, a trailblazer in microbiological solutions for agriculture and viticulture which has successfully raised € 900,000 in seed only 2️⃣ mouths after the company was founded! ➡️This investment is a strategic move towards addressing the challenges of sustainable agriculture and acknowledges the rising interest in the microbiomes of food systems. ➡️It aligns with the global shift towards sustainable practices in agriculture, food production, and overall ecosystem health. #DeeptechGreen #Biotech #Agtech #Winetech #Microbiome
-
-
"For many years, at Seventure Partners, through our Health For Life Captal™ I & II funds, we have been investing in technologies and research sectors that respond to major societal and environmental challenges. The microbiome, our field of excellence for over 10 years, is now the focus of attention in all sectors involving agriculture, nutrition and health. I'm delighted to see that the World Economic Forum has taken up this topic. Respecting the microbiome of soils and crops means better protecting human health. We are very close to the biotech companies that are enhancing the value of micro-organisms for more responsible agriculture, and we invite you to keep an eye on our forthcoming announcement", comments our CEO Isabelle de Cremoux. World Economic Forum #Microbiome #AgTech #FoodScience #Investments https://lnkd.in/eXmHNewR
Did you know there is a connection between your gut and the soil? | World Economic Forum
weforum.org
-
Retrouvez la tribune de notre CEO Isabelle de Cremoux publiée ce jour dans Les Echos sur un des secteurs économiques des plus dynamique : Le SPORT ! "Pour un investisseur, le secteur du sport représente donc un terrain de jeu prometteur pour la diversification de son portefeuille. L'univers d'investissement est non seulement immense, mais il est également en expansion continue : chaque année, ce sont ainsi plus de 300 sociétés non cotées européennes qui lèvent des fonds afin de financer leur croissance." Lire l'intégralité 👉 https://lnkd.in/gacvqwNd 🚀 Bpifrance : Joignons nos forces pour continuer à propulser la #sportech française à l'aube des #JO #Paris2024 ! 🏅
Opinion | Le sport, terrain de jeu pour diversifier son portefeuille
lesechos.fr
-
📢 Exciting News! Enterome Joins LLS TAP to Accelerate Breakthrough Blood Cancer Therapeutics 🚀 Enterome has been selected to be a part of The Leukemia & Lymphoma Society's Therapy Acceleration Program® (LLS TAP) – a groundbreaking initiative aimed at fast-tracking innovative treatments for blood cancers. 🩸 With a strategic equity investment of €3 million, LLS TAP is joining forces with Enterome to drive the clinical advancement of EO2463 in Non-Hodgkin's Lymphoma. This substantial investment is a significant step towards transforming the landscape of blood cancer therapeutics and bringing hope to patients worldwide. 💪 Fulle press release 👉 https://lnkd.in/epTkxZkM #Microbiome #Cancer #Research #Leukemia Belichard Pierre Isabelle de Cremoux The Leukemia & Lymphoma Society
-